Medical Pharmacology: Cancer Chemotherapy
Anti-Metabolite (Anti-Microtubule) Practice Questions
Click on the correct answer.
L-asparaginase (an anticancer agent) may decrease liver-mediated Vinca alkaloid clearance, possibly resulting in increased incidence of Vinca alkaloid-related toxicities.
True
False
Vinca alkaloid administration seizures:
Vinca alkaloid administration results in a seizure-protective effect, allowing for discontinuation of antiepileptic agents such as phenytoin.
Vinca alkaloid administration tends to decrease plasma phenytoin levels, intern resulting in seizures.
Which one(s) of the following toxicities are associated with vinblastine and vinorelbine?
Neutropenia
Thrombocytopenia
Anemia
A & B
B & C
A, B & C
Vinca alkaloid infusion may increase the risk of phlebitis in the vein used to administer the drug.
True
False
Estramustine phosphate (Emcyt):
Classified as a microtubule antagonist
Approved for administration to patients with castration-resistant prostate cancer (CRPC)
Both
Neither
Maytansinoids and auristatins (tubulin-binding drugs) are examples of highly potent anticancer agents which have been investigated in terms of antibody drug conjugates space (ADC).
True
False
Maytansinoid-1:
This agent exhibits anti-microtubule characteristics
Maytansinoid-1 administered as an antibody drug conjugate (ado-trastuzumab emtansine) is FDA-approved for individuals with HER-2-positive metastatic breast cancer.
Both
Neither
Auristatin (auristatin-E, an anti-microtubule agent) link to a monoclonal antibody (CD30) has been approved for refractory Hodgkin's lymphoma or anaplastic large cell lymphoma.
True
False
Example(s) of mitotic motor protein inhibitor(s):
Aurora kinases
Pololike kinase inhibitors
Both
Neither
The MDR1 (a multi-drug-resistant gene product, and ABC transporter) appears responsible for drug resistance to the taxane-class of anti-microtubule drugs.
